Gram-negative bacteria are a group of bacteria that do not retain the crystal violet stain used in the gram-staining method of bacterial differentiation. They are characterized by their cell envelopes, which are composed of a thin peptidoglycancell wall sandwiched between an inner cytoplasmiccell membrane and a bacterial outer membrane.
Gram-negative bacteria are found everywhere, in virtually all environments on Earth that support life. The gram-negative bacteria include the model organismEscherichia coli, as well as many pathogenic bacteria, such as Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia trachomatis, and Yersinia pestis. They are an important medical challenge, as their outer membrane protects them from many antibiotics (including penicillin); detergents that would normally damage the peptidoglycans of the (inner) cell membrane; and lysozyme, an antimicrobial enzyme produced by animals that forms part of the innate immune system. Additionally, the outer leaflet of this membrane comprises a complex lipopolysaccharide (LPS) whose lipid A component can cause a toxic reaction when these bacteria are lysed by immune cells. This toxic reaction can include fever, an increased respiratory rate, and low blood pressure — a life-threatening condition known as septic shock.
Several classes of antibiotics have been designed to target gram-negative bacteria, including aminopenicillins, ureidopenicillins, cephalosporins, beta-lactam-betalactamase combinations (e.g. pipercillin-tazobactam), Folate antagonists, quinolones, and carbapenems. Many of these antibiotics also cover gram positive organisms. The drugs that specifically target gram negative organisms include aminoglycosides, monobactams (aztreonam) and Ciprofloxacin.
Gram-negative bacteria display these characteristics:
- An inner cell membrane is present (cytoplasmic)
- A thin peptidoglycan layer is present (This is much thicker in gram-positive bacteria)
- Has outer membrane containing lipopolysaccharides (LPS, which consists of lipid A, core polysaccharide, and O antigen) in its outer leaflet and phospholipids in the inner leaflet
- Porins exist in the outer membrane, which act like pores for particular molecules
- Between the outer membrane and the cytoplasmic membrane there is a space filled with a concentrated gel-like substance called periplasm
- The S-layer is directly attached to the outer membrane rather than to the peptidoglycan
- If present, flagella have four supporting rings instead of two
- Teichoic acids or lipoteichoic acids are absent
- Lipoproteins are attached to the polysaccharide backbone
- Some contain Braun's lipoprotein, which serves as a link between the outer membrane and the peptidoglycan chain by a covalent bond
- Most, with very few exceptions, do not form spores
Along with cell shape, gram-staining is a rapid diagnostic tool and once was used to group species at the subdivision of Bacteria. Historically, the kingdom Monera was divided into four divisions based on gram-staining: Firmacutes (+), Gracillicutes (−), Mollicutes (0) and Mendocutes (var.). Since 1987, the monophyly of the gram-negative bacteria has been disproven with molecular studies. However some authors, such as Cavalier-Smith still treat them as a monophyletic taxon (though not a clade; his definition of monophyly requires a single common ancestor but does not require holophyly, the property that all descendents be encompassed by the taxon) and refer to the group as a subkingdom "Negibacteria".
Bacteria are traditionally divided into the two groups: gram-positive and gram-negative, based on their gram-staining response. Gram-positive bacteria are also referred to as monoderms having one membrane, and gram-negative bacteria are also referred to as diderms, having two membranes. These groups are often thought of as lineages, with gram-negative bacteria more closely related to one another than to gram-positive bacteria. While this is often true, the classification system breaks down in some cases. A given bacteria's staining result, bacterial membrane organization, and lineage groupings do not always match up. Thus, gram-staining cannot be reliably used to assess familial relationships of bacteria. However, staining often gives reliable information about the composition of the cell membrane, distinguishing between the presence or absence of an outer lipid membrane.
Of these two structurally distinct groups of prokaryotic organisms, monoderm prokaryotes are indicated to be ancestral. Based upon a number of different observations including that the gram-positive bacteria are the major reactors to antibiotics and that gram-negative bacteria are, in general, resistant to them, it has been proposed that the outer cell membrane in gram-negative bacteria (diderms) evolved as a protective mechanism against antibiotic selection pressure. Some bacteria such as Deinococcus, which stain gram-positive due to the presence of a thick peptidoglycan layer, but also possess an outer cell membrane are suggested as intermediates in the transition between monoderm (gram-positive) and diderm (gram-negative) bacteria. The diderm bacteria can also be further differentiated between simple diderms lacking lipopolysaccharide; the archetypical diderm bacteria, in which the outer cell membrane contains lipopolysaccharide; and the diderm bacteria, in which the outer cell membrane is made up of mycolic acid (e. g. Mycobacterium).
In addition, a number of bacterial taxa (including Negativicutes, Fusobacteria, Synergistetes, and Elusimicrobia) that are either part of the phylum Firmicutes or branches in its proximity are also found to possess a diderm cell structure. However, a conserved signature indel (CSI) in the HSP60 (GroEL) protein distinguishes all traditional phyla of gram-negative bacteria (e.g., Proteobacteria, Aquificae, Chlamydiae, Bacteroidetes, Chlorobi, Cyanobacteria, Fibrobacteres, Verrucomicrobia, Planctomycetes, Spirochetes, Acidobacteria) from these other atypical diderm bacteria as well as other phyla of monoderm bacteria (e.g., Actinobacteria, Firmicutes, Thermotogae, Chloroflexi). The presence of this CSI in all sequenced species of conventional lipopolysaccharide-containing gram-negative bacterial phyla provides evidence that these phyla of bacteria form a monophyletic clade and that no loss of the outer membrane from any species from this group has occurred.
The proteobacteria are a major phylum of gram-negative bacteria, including Escherichia coli (E. coli), Salmonella, Shigella, and other Enterobacteriaceae, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, Bdellovibrio, acetic acid bacteria, Legionella etc. Other notable groups of gram-negative bacteria include the cyanobacteria, spirochaetes, green sulfur, and green non-sulfur bacteria.
Medically relevant gram-negative cocci include the four types that cause a sexually transmitted disease (Neisseria gonorrhoeae), a meningitis (Neisseria meningitidis), and respiratory symptoms (Moraxella catarrhalis, Haemophilus influenzae).
Medically relevant gram-negative bacilli include a multitude of species. Some of them cause primarily respiratory problems (Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa), primarily urinary problems (Escherichia coli, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens), and primarily gastrointestinal problems (Helicobacter pylori, Salmonella enteritidis, Salmonella typhi).
Gram-negative bacteria associated with hospital-acquired infections include Acinetobacter baumannii, which cause bacteremia, secondary meningitis, and ventilator-associated pneumonia in hospital intensive-care units.
Transformation is one of three processes for horizontal gene transfer, in which exogenous genetic material passes from bacterium to another, the other two being conjugation (transfer of genetic material between two bacterial cells in direct contact) and transduction (injection of foreign DNA by a bacteriophage virus into the host bacterium). In transformation, the genetic material passes through the intervening medium, and uptake is completely dependent on the recipient bacterium.
As of 2014 about 80 species of bacteria were known to be capable of transformation, about evenly divided between Gram-positive and Gram-negative bacteria; the number might be an overestimate since several of the reports are supported by single papers. Transformation has been studied in medically important Gram-negative bacteria species such as Helicobacter pylori, Legionella pneumophila, Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae and Vibrio cholerae. It has also been studied in gram-negative species found in soil such as Pseudomonas stutzeri, Acinetobacter baylyi, and gram-negative plant pathogens such as Ralstonia solanacearum and Xylella fastidiosa.
One of the several unique characteristics of gram-negative bacteria is the structure of the bacterial outer membrane. The outer leaflet of this membrane comprises a complex lipopolysaccharide (LPS) whose lipid portion acts as an endotoxin. If gram-negative bacteria enter the circulatory system, the liposaccharide can cause a toxic reaction. This results in fever, an increased respiratory rate, and low blood pressure. This may lead to life-threatening septic shock.
The outer membrane protects the bacteria from several antibiotics, dyes, and detergents that would normally damage either the inner membrane or the cell wall (made of peptidoglycan). The outer membrane provides these bacteria with resistance to lysozyme and penicillin. The periplasmic space (space between the two cell membranes) also contains enzymes which break down or modify antibiotics. Drugs commonly used to treat gram negative infections include amino, carboxy and ureido penicillins (ampicillin, amoxicillin, pipercillin, ticarcillin) these drugs may be combined with beta-lactamase inhibitors to combat the presence of enzymes that can digest these drugs (known as beta-lactamases) in the peri-plasmic space. Other classes of drugs that have gram negative spectrum include cephalosporins, monobactams (aztreonam), aminogylosides, quinolones, macrolides, chloramphenicol, folate antagonists, and carbapenems.
The pathogenic capability of gram-negative bacteria is often associated with certain components of their membrane, in particular, the LPS. In humans, the presence of LPS triggers an innate immune response, activating the immune system and producing cytokines (hormonal regulators). Inflammation is a common reaction to cytokine production, which can also produce host toxicity. The innate immune response to LPS, however, is not synonymous with pathogenicity, or the ability to cause disease.
The adjectives Gram-positive and Gram-negative derive from the surname of Hans Christian Gram, a Danish bacteriologist; as eponymous adjectives, their initial letter can be either capital G or lower-case g, depending on which style guide (e.g., that of the CDC), if any, governs the document being written. This is further explained at Gram staining § Orthographic note.
- ^ abBaron S, Salton MR, Kim KS (1996). "Structure". In Baron S, et al. Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1. PMID 21413343.
- ^ abPellitier LL Jr, "Microbiology of the Circulatory System" "NCBI Bookshelf", April 18, 2017
- ^Gibbons, N. E.; Murray, R. G. E. (1978). "Proposals Concerning the Higher Taxa of Bacteria". International Journal of Systematic Bacteriology. 28 (1): 1–6. doi:10.1099/00207713-28-1-1.
- ^Woese CR (June 1987). "Bacterial evolution". Microbiol. Rev. 51 (2): 221–71. PMC 373105. PMID 2439888.
- ^Cavalier-Smith, T. (2006). "Rooting the tree of life by transition analyses". Biol. Direct. 1: 19. doi:10.1186/1745-6150-1-19. PMC 1586193. PMID 16834776.
- ^ abcdGupta RS (December 1998). "Protein phylogenies and signature sequences: A reappraisal of evolutionary relationships among archaebacteria, eubacteria, and eukaryotes". Microbiol. Mol. Biol. Rev. 62 (4): 1435–91. PMC 98952. PMID 9841678.
- ^ abGupta RS (2000). "The natural evolutionary relationships among prokaryotes"(PDF). Crit. Rev. Microbiol. 26 (2): 111–31. doi:10.1080/10408410091154219. PMID 10890353.
- ^ abDesvaux M, Hébraud M, Talon R, Henderson IR (April 2009). "Secretion and subcellular localizations of bacterial proteins: a semantic awareness issue". Trends Microbiol. 17 (4): 139–45. doi:10.1016/j.tim.2009.01.004. PMID 19299134.
- ^ abcSutcliffe IC (October 2010). "A phylum level perspective on bacterial cell envelope architecture". Trends Microbiol. 18 (10): 464–70. doi:10.1016/j.tim.2010.06.005. PMID 20637628.
- ^ abGupta RS (August 1998). "What are archaebacteria: life's third domain or monoderm prokaryotes related to gram-positive bacteria? A new proposal for the classification of prokaryotic organisms". Mol. Microbiol. 29 (3): 695–707. doi:10.1046/j.1365-2958.1998.00978.x. PMID 9723910.
- ^ abcdefGupta RS (August 2011). "Origin of diderm (gram-negative) bacteria: antibiotic selection pressure rather than endosymbiosis likely led to the evolution of bacterial cells with two membranes". Antonie Van Leeuwenhoek. 100 (2): 171–82. doi:10.1007/s10482-011-9616-8. PMC 3133647. PMID 21717204.
- ^ abMarchandin H, Teyssier C, Campos J, Jean-Pierre H, Roger F, Gay B, Carlier JP, Jumas-Bilak E (June 2010). "Negativicoccus succinicivorans gen. nov., sp. nov., --~~~~isolated from human clinical samples, emended description of the family Veillonellaceae any classis nov., Selenomonadales ord. nov. and Acidaminococcaceae fam. nov. in the bacterial phylum Firmicutes". Int. J. Syst. Evol. Microbiol. 60 (Pt 6): 1271–9. doi:10.1099/ijs.0.013102-0. PMID 19667386.
- ^ abcJohnston C, Martin B, Fichant G, Polard P, Claverys JP (2014). "Bacterial transformation: distribution, shared mechanisms and divergent control". Nat. Rev. Microbiol. 12 (3): 181–96. doi:10.1038/nrmicro3199. PMID 24509783.
- ^ abSeitz P, Blokesch M (2013). "Cues and regulatory pathways involved in natural competence and transformation in pathogenic and environmental Gram-negative bacteria". FEMS Microbiol. Rev. 37 (3): 336–63. doi:10.1111/j.1574-6976.2012.00353.x. PMID 22928673.
- ^"Preferred Usage - Emerging Infectious Disease journal - CDC". CDC.gov. Centers for Disease Control and Prevention.
1. LaRosa SP, Opal SM. Sepsis strategies in development. Clin Chest Med. 2008;29:735–47, x-xi. doi: 10.1016/j.ccm.2008.06.007.[PubMed][Cross Ref]
2. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol. 2005;175:6465–72.[PubMed]
3. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130:906–17. doi: 10.1016/j.cell.2007.08.002.[PubMed][Cross Ref]
4. Solomon SB, Cui X, Gerstenberger E, Danner RL, Fitz Y, Banks SM, Natanson C, Eichacker PQ. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis. 2006;193:634–44. doi: 10.1086/500147.[PubMed][Cross Ref]
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10. doi: 10.1097/00003246-200107000-00002.[PubMed][Cross Ref]
6. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227–42. doi: 10.7326/0003-4819-113-3-227.[PubMed][Cross Ref]
7. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54. doi: 10.1056/NEJMoa022139.[PubMed][Cross Ref]
8. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin Infect Dis. 2003;37:50–8. doi: 10.1086/375593.[PubMed][Cross Ref]
9. Bergsten G, Samuelsson M, Wullt B, Leijonhufvud I, Fischer H, Svanborg C. PapG-dependent adherence breaks mucosal inertia and triggers the innate host response. J Infect Dis. 2004;189:1734–42. doi: 10.1086/383278.[PubMed][Cross Ref]
10. Merrell DS, Falkow S. Frontal and stealth attack strategies in microbial pathogenesis. Nature. 2004;430:250–6. doi: 10.1038/nature02760.[PubMed][Cross Ref]
11. Proft T, Sriskandan S, Yang L, Fraser JD. Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis. 2003;9:1211–8. doi: 10.3201/eid0910.030042.[PMC free article][PubMed][Cross Ref]
12. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32–43. doi: 10.1016/S1473-3099(07)70265-7.[PubMed][Cross Ref]
13. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. doi: 10.1016/j.cell.2006.02.015.[PubMed][Cross Ref]
14. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417–32. doi: 10.1146/annurev.med.38.1.417.[PubMed][Cross Ref]
15. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med. 1991;114:332–3. doi: 10.7326/0003-4819-114-4-332.[PubMed][Cross Ref]
16. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635–700. doi: 10.1146/annurev.biochem.71.110601.135414.[PMC free article][PubMed][Cross Ref]
17. Galloway SM, Raetz CR. A mutant of Escherichia coli defective in the first step of endotoxin biosynthesis. J Biol Chem. 1990;265:6394–402.[PubMed]
18. Guan Z, Breazeale SD, Raetz CR. Extraction and identification by mass spectrometry of undecaprenyl diphosphate-MurNAc-pentapeptide-GlcNAc from Escherichia coli. Anal Biochem. 2005;345:336–9. doi: 10.1016/j.ab.2005.07.002.[PubMed][Cross Ref]
19. Schromm AB, Brandenburg K, Loppnow H, Zähringer U, Rietschel ET, Carroll SF, Koch MH, Kusumoto S, Seydel U. The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity. J Immunol. 1998;161:5464–71.[PubMed]
20. Schromm AB, Brandenburg K, Loppnow H, Moran AP, Koch MH, Rietschel ET, Seydel U. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem. 2000;267:2008–13. doi: 10.1046/j.1432-1327.2000.01204.x.[PubMed][Cross Ref]
21. Somerville JE, Jr., Cassiano L, Darveau RP. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect Immun. 1999;67:6583–90.[PMC free article][PubMed]
22. Girard R, Pedron T, Uematsu S, Balloy V, Chignard M, Akira S, Chaby R. Lipopolysaccharides from Legionella and Rhizobium stimulate mouse bone marrow granulocytes via Toll-like receptor 2. J Cell Sci. 2003;116:293–302. doi: 10.1242/jcs.00212.[PubMed][Cross Ref]
23. Moran AP, Lindner B, Walsh EJ. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. J Bacteriol. 1997;179:6453–63.[PMC free article][PubMed]
24. Smith MF, Jr., Mitchell A, Li G, Ding S, Fitzmaurice AM, Ryan K, Crowe S, Goldberg JB. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem. 2003;278:32552–60. doi: 10.1074/jbc.M305536200.[PubMed][Cross Ref]
25. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505–18. doi: 10.1146/annurev.bi.57.070188.002445.[PubMed][Cross Ref]
26. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627–52.[PubMed]
27. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005;3:36–46. doi: 10.1038/nrmicro1068.[PubMed][Cross Ref]
28. Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol. 2010;8:8–14.[PubMed]
29. Medzhitov R, Preston-Hurlburt P, Janeway CA., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–7. doi: 10.1038/41131.[PubMed][Cross Ref]
30. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science. 1990;249:1429–31. doi: 10.1126/science.2402637.[PubMed][Cross Ref]
31. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3. doi: 10.1126/science.1698311.[PubMed][Cross Ref]
32. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999;189:1777–82. doi: 10.1084/jem.189.11.1777.[PMC free article][PubMed][Cross Ref]
33. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002;3:667–72.[PubMed]
34. Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, Weiss JP. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci U S A. 2004;101:4186–91. doi: 10.1073/pnas.0306906101.[PMC free article][PubMed][Cross Ref]
35. Feng C, Stamatos NM, Dragan AI, Medvedev A, Whitford M, Zhang L, Song C, Rallabhandi P, Cole L, Nhu QM, et al. Sialyl residues modulate LPS-mediated signaling through the Toll-like receptor 4 complex. PLoS One. 2012;7:e32359. doi: 10.1371/journal.pone.0032359.[PMC free article][PubMed][Cross Ref]
36. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–8. doi: 10.1126/science.282.5396.2085.[PubMed][Cross Ref]
37. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51. doi: 10.1016/j.cyto.2008.01.006.[PubMed][Cross Ref]
38. Bannerman DD, Erwert RD, Winn RK, Harlan JM. TIRAP mediates endotoxin-induced NF-kappaB activation and apoptosis in endothelial cells. Biochem Biophys Res Commun. 2002;295:157–62. doi: 10.1016/S0006-291X(02)00638-1.[PubMed][Cross Ref]
39. Delvos U, Janssen B, Müller-Berghaus G. Effect of lipopolysaccharides on cultured human endothelial cells. Relationship between tissue factor activity and prostacyclin release. Blut. 1987;55:101–8. doi: 10.1007/BF00631779.[PubMed][Cross Ref]
40. Suttorp N, Galanos C, Neuhof H. Endotoxin alters arachidonate metabolism in pulmonary endothelial cells. Am J Physiol. 1987;253:C384–90.[PubMed]
41. Ernst RK, Guina T, Miller SI. Salmonella typhimurium outer membrane remodeling: role in resistance to host innate immunity. Microbes Infect. 2001;3:1327–34. doi: 10.1016/S1286-4579(01)01494-0.[PubMed][Cross Ref]
42. Pinheiro da Silva F, Machado MC. Antimicrobial peptides: clinical relevance and therapeutic implications. Peptides. 2012;36:308–14. doi: 10.1016/j.peptides.2012.05.014.[PubMed][Cross Ref]
43. Guo L, Lim KB, Gunn JS, Bainbridge B, Darveau RP, Hackett M, Miller SI. Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-phoQ. Science. 1997;276:250–3. doi: 10.1126/science.276.5310.250.[PubMed][Cross Ref]
44. Kawasaki K, Ernst RK, Miller SI. 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling through Toll-like receptor 4. J Biol Chem. 2004;279:20044–8. doi: 10.1074/jbc.M401275200.[PubMed][Cross Ref]
45. Guo L, Lim KB, Poduje CM, Daniel M, Gunn JS, Hackett M, Miller SI. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell. 1998;95:189–98. doi: 10.1016/S0092-8674(00)81750-X.[PubMed][Cross Ref]
46. Trent MS, Pabich W, Raetz CR, Miller SI. A PhoP/PhoQ-induced Lipase (PagL) that catalyzes 3-O-deacylation of lipid A precursors in membranes of Salmonella typhimurium. J Biol Chem. 2001;276:9083–92. doi: 10.1074/jbc.M010730200.[PubMed][Cross Ref]
47. Bishop RE, Gibbons HS, Guina T, Trent MS, Miller SI, Raetz CR. Transfer of palmitate from phospholipids to lipid A in outer membranes of gram-negative bacteria. EMBO J. 2000;19:5071–80. doi: 10.1093/emboj/19.19.5071.[PMC free article][PubMed][Cross Ref]
48. Gibbons HS, Lin S, Cotter RJ, Raetz CR. Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A. Function of LpxO, A new Fe2+/alpha-ketoglutarate-dependent dioxygenase homologue. J Biol Chem. 2000;275:32940–9. doi: 10.1074/jbc.M005779200.[PubMed][Cross Ref]
49. Gunn JS, Ryan SS, Van Velkinburgh JC, Ernst RK, Miller SI. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium. Infect Immun. 2000;68:6139–46. doi: 10.1128/IAI.68.11.6139-6146.2000.[PMC free article][PubMed][Cross Ref]
50. Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, Hackett M, Miller SI. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science. 1999;286:1561–5. doi: 10.1126/science.286.5444.1561.[PubMed][Cross Ref]
51. Tracey KJ, Lowry SF. The role of cytokine mediators in septic shock. Adv Surg. 1990;23:21–56.[PubMed]
52. Beutler B. Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock. New Horiz. 1993;1:3–12.[PubMed]
53. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869–71. doi: 10.1126/science.3895437.[PubMed][Cross Ref]
54. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, 3rd, Zentella A, Albert JD, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470–4. doi: 10.1126/science.3764421.[PubMed][Cross Ref]
55. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem. 1988;263:13479–81.[PubMed]
56. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662–4. doi: 10.1038/330662a0.[PubMed][Cross Ref]
57. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock. 1995;3:1–12.[PubMed]
58. Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798–802. doi: 10.1038/364798a0.[PubMed][Cross Ref]
59. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457–67. doi: 10.1016/0092-8674(93)90134-C.[PubMed][Cross Ref]
60. Dinarello CA. The role of interleukin-1 in host responses to infectious diseases. Infect Agents Dis. 1992;1:227–36.[PubMed]
61. Wang R, Fang Q, Zhang L, Radvany L, Sharma A, Noben-Trauth N, Mills GB, Shi Y. CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol. 1997;158:2856–61.[PubMed]
62. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A. 1990;87:3629–32. doi: 10.1073/pnas.87.9.3629.[PMC free article][PubMed][Cross Ref]
63. Kettelhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci U S A. 1987;84:4273–7. doi: 10.1073/pnas.84.12.4273.[PMC free article][PubMed][Cross Ref]
64. Benjamim CF, Silva JS, Fortes ZB, Oliveira MA, Ferreira SH, Cunha FQ. Inhibition of leukocyte rolling by nitric oxide during sepsis leads to reduced migration of active microbicidal neutrophils. Infect Immun. 2002;70:3602–10. doi: 10.1128/IAI.70.7.3602-3610.2002.[PMC free article][PubMed]